Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.74 |
| ▸ | SELL | P14151 | 1/20 | 0.51 |
| ▸ | SELP | P16109 | 1/20 | 0.51 |
| ▸ | MAG | P20916 | 3/20 | 0.48 |
| ▸ | SIGLEC7 | Q9Y286 | 7/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CD22 | P20273 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28161285 | 1.00 | NANP (0.74) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL15976325 | 1.00 | NANP (0.74) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL13125452 | 1.00 | NANP (0.74) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL8489507 | 1.00 | NANP (0.74) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL2742889 | 1.00 | NANP (0.74) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL8664558 | 0.92 | NANP (0.64) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL9253179 | 0.92 | NANP (0.63) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL14601223 | 0.91 | NANP (0.63) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL23366254 | 0.91 | NANP (0.74) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL7263212 | 0.91 | NANP (0.62) | NANPSELLSELPMAGSIGLEC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119139331-A | Use of sialic acid esters | 铭畅生物医药南通有限公司 | 2024-12-17 | — | — | CN | claimed |
| US-20260069656-A1 | Nutritive Polypeptides and Formulations Thereof, and Methods of Production and Use Thereof | AXCELLA HEALTH INC (US) | 2026-03-12 | — | — | US | disclosed |
| CN-120137003-A | Method for chemically synthesizing glycosylated insulin | 中国医学科学院药物研究所 | 2025-06-13 | — | — | CN | disclosed |
| CN-120137003-A | Method for chemically synthesizing glycosylated insulin | 中国医学科学院药物研究所 | 2025-06-13 | — | — | CN | disclosed |
| CN-116479073-B | Method for synthesizing sialic acid ester by catalyzing sialic acid through semi-enzyme method and application | 铭畅生物医药南通有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119139331-A | Use of sialic acid esters | 铭畅生物医药南通有限公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-118178673-B | Sialic acid ester cyclodextrin inclusion compound and preparation method and application thereof | 铭畅生物医药南通有限公司 | 2024-11-05 | — | — | CN | disclosed |
| CN-118697696-A | Anrotinib nano preparation and preparation method and application thereof | 广州制高点医药科技有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-118420900-A | Multivalent sialic acid polymer and preparation method and application thereof | 中国科学院长春应用化学研究所 | 2024-08-02 | — | — | CN | disclosed |
| CN-118178673-A | Sialic acid ester cyclodextrin inclusion compound and preparation method and application thereof | 铭畅生物医药南通有限公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-3048900-A2 | COMPOSITIONS AND FORMULATIONS FOR PREVENTION AND REDUCTION OF TUMORIGENESIS, CANCER CELL PROLIFERATION AND INVASION, AND METHODS OF PRODUCTION AND USE THEREOF IN CANCER TREATMENT | Pronutria Biosciences, Inc. (US) | 2016-08-03 | — | — | EP | disclosed |
| WO-2015048339-A9 | COMPOSITIONS AND FORMULATIONS FOR NON-HUMAN NUTRITION AND METHODS OF PRODUCTION AND USE THEREOF | PRONUTRIA, INC. (US) | 2015-07-02 | — | — | WO | disclosed |
| WO-2015054507-A1 | NUTRITIVE POLYPEPTIDE PRODUCTION SYSTEMS, AND METHODS OF MANUFACTURE AND USE THEREOF | PRONUTRIA, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015048342-A2 | COMPOSITIONS AND FORMULATIONS FOR MAINTAINING AND INCREASING MUSCLE MASS, STRENGTH, AND PERFORMANCE AND METHODS OF PRODUCTION AND USE THEREOF | PRONUTRIA, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| CN-100523188-C | Platlet glycoprotein IB alpha fusion polypeptides and methods of use thereof | INST GENETICS LLC (US) | 2009-08-05 | — | — | CN | disclosed |
| CN-1553955-A | Platlet glycoprotein IB alpha fusion polypeptides and methods of use thereof | �Ŵ�ѧԺ�������ι�˾ | 2004-12-08 | — | — | CN | disclosed |
| WO-2003049547-A2 | DAIRY PROCESS AND PRODUCT | NEW ZEALAND DAIRY BOARD (NZ) | 2003-06-19 | — | — | WO | disclosed |
| US-6447991-B1 | DETECTION AND IDENTIFICATION OF BIOAEROSOLS, INCLUDING BACTERIA, VIRUSES, TOXINS, AND OTHER BIOAEROSOLS. AEROGELS, EXTREMELY LOW DENSITY AND HIGHLY POROUS MATERIALS WITH A COMPLEX PORE STRUCTURE, ARE USED AS AN INTELLIGENT DETECTION | UAB RESEARCH FOUNDATION, THE | 2002-09-10 | — | — | US | disclosed |
| WO-1999043743-A9 | SMART AEROGEL | PACIFIC SIERRA RESEARCH INC (US) | 2000-01-27 | — | — | WO | disclosed |
| WO-1999043743-A1 | SMART AEROGEL | PACIFIC-SIERRA RESEARCH, INC. (US) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069656-A1 | Nutritive Polypeptides and Formulations Thereof, and Methods of Production and Use Thereof | TTPA, VIP, GC | NANP 2232/4885SELL 1270/4885SELP 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.